

# John W Babich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3169372/publications.pdf>

Version: 2024-02-01

173  
papers

7,548  
citations

47006

47  
h-index

66911

78  
g-index

176  
all docs

176  
docs citations

176  
times ranked

5971  
citing authors

#	ARTICLE	IF	CITATIONS
1	68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study. <i>Translational Oncology</i> , 2022, 15, 101242.	3.7	10
2	PET Tracers for Imaging Cardiac Function in Cardio-oncology. <i>Current Cardiology Reports</i> , 2022, 24, 247-260.	2.9	12
3	Synthesis and Evaluation of 11C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography. <i>Molecules</i> , 2022, 27, 1552.	3.8	0
4	Decreased CSF clearance and increased brain amyloid in Alzheimer's disease. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 21.	5.0	41
5	Advances in PSMA theranostics. <i>Translational Oncology</i> , 2022, 22, 101450.	3.7	21
6	A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS188-TPS188.	1.6	2
7	In Vivo Imaging of Fibroblast Activity Using a 68Ga-Labeled Fibroblast Activation Protein Alpha (FAP- $\hat{\pm}$ ) Inhibitor. <i>Journal of Bone and Joint Surgery - Series A</i> , 2021, 103, e40.	3.0	7
8	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120.	1.6	1
9	A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein- $\hat{\pm}$ (FAP $\hat{\pm}$ ). <i>Molecular Imaging and Biology</i> , 2021, 23, 686-696.	2.6	15
10	Population-based input function for TSPO quantification and kinetic modeling with [11C]-DPA-713. <i>EJNMMI Physics</i> , 2021, 8, 39.	2.7	6
11	Phase I study of <sup>225</sup> Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5015-5015.	1.6	24
12	A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 38.	3.9	15
13	Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates. <i>Human Gene Therapy</i> , 2020, 31, 1237-1259.	2.7	21
14	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	2.3	16
15	Otto: a 4.04 GBq (109 mCi) 68Ge/68Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [68Ga]Ga-PSMA-11. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 5.	3.9	9
16	Oxyaapa: A Picolinate-Based Ligand with Five Oxygen Donors that Strongly Chelates Lanthanides. <i>Inorganic Chemistry</i> , 2020, 59, 5116-5132.	4.0	14
17	Synthesis of [ <sup>11</sup> C]Butanol via a facile solid phase extraction protocol. <i>Applied Radiation and Isotopes</i> , 2020, 159, 109078.	1.5	2
18	A general 11C-labeling approach enabled by fluoride-mediated desilylation of organosilanes. <i>Nature Communications</i> , 2020, 11, 1736.	12.8	14

#	ARTICLE	IF	CITATIONS
19	Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for <sup>64</sup> Cu/ <sup>67</sup> Cu-Based Theranostics in Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2020, 17, 1954-1962.	4.6	28
20	Phase I dose-escalation study of PSMA-targeted alpha emitter <sup>225</sup> Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5560-5560.	1.6	9
21	Dose-escalation results of a phase I study of <sup>225</sup> Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 114-114.	1.6	17
22	Feasibility of Population-Based Input Function for Kinetic Analysis of [ <sup>11</sup> C]-DPA-713. , 2020, , .		1
23	Physical Performance of SynchroPET ArterialPET, a Human Wrist PET Prototype Scanner for Non-Invasive Arterial Input Function Evaluation. , 2020, , .		0
24	Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 40-69.	10.5	88
25	Improved synthesis of the bifunctional chelator <i>p</i> -SCN-Bn-HOPO. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 6866-6871.	2.8	12
26	3D-printed automation for optimized PET radiochemistry. <i>Science Advances</i> , 2019, 5, eaax4762.	10.3	6
27	Defining the origins of multiple emission/excitation in rhenium-bisthiazole complexes. <i>Inorganica Chimica Acta</i> , 2019, 489, 301-309.	2.4	4
28	[ <sup>18</sup> F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4. <i>Molecules</i> , 2019, 24, 1612.	3.8	8
29	Preclinical evaluation of peptide-based radiotracers for integrin $\alpha_6\beta_1$ -positive pancreatic carcinoma. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, 309-318.	0.7	8
30	Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window. <i>Journal of Nuclear Medicine</i> , 2019, 60, 656-663.	5.0	48
31	A Single Dose of <sup>225</sup> Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model. <i>Journal of Nuclear Medicine</i> , 2019, 60, 649-655.	5.0	55
32	Phase I/II dose-escalation trial of fractionated dose <sup>177</sup> Lu-J591 plus <sup>177</sup> Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3339-TPS3339.	1.6	1
33	Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1841-1851.	6.4	56
34	Intraindividual Comparison of <sup>99m</sup> Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand <sup>99m</sup> Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1373-1379.	5.0	31
35	[ <sup>18</sup> F]RPS-544: A PET tracer for imaging the chemokine receptor CXCR4. <i>Nuclear Medicine and Biology</i> , 2018, 60, 37-44.	0.6	13
36	<sup>66</sup> Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?. <i>Molecules</i> , 2018, 23, 2575.	3.8	9

#	ARTICLE	IF	CITATIONS
37	Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets. <i>Journal of Neuroinflammation</i> , 2018, 15, 272.	7.2	18
38	Impact of elution impurities on DOTA and NOTA labeling with two commercial <sup>68</sup> Ge/ <sup>68</sup> Ga generators. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 317, 1485-1490.	1.5	2
39	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. <i>Clinical Cancer Research</i> , 2018, 24, 6300-6307.	7.0	112
40	Phase I dose-escalation study of <sup>225</sup> Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS399-TPS399.	1.6	20
41	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with <sup>131</sup> I-MIP-1095. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 950-959.	6.4	69
42	Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1442-1449.	5.0	61
43	Differential in radiosensitizing potency of enantiomers of the fatty acid synthase inhibitor C75. <i>Chirality</i> , 2017, 29, 10-13.	2.6	6
44	Phase 2 Study of <sup>99m</sup> Tc-Trofolostat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1408-1413.	5.0	63
45	An Eighteen-Membered Macrocyclic Ligand for Actinium- <sup>225</sup> Targeted Alpha Therapy. <i>Angewandte Chemie</i> , 2017, 129, 14904-14909.	2.0	9
46	An Eighteen-Membered Macrocyclic Ligand for Actinium- <sup>225</sup> Targeted Alpha Therapy. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 14712-14717.	13.8	163
47	Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. <i>Journal of Nuclear Medicine</i> , 2017, 58, 17S-26S.	5.0	111
48	Identification of Ligands and Translation to Clinical Applications. <i>Journal of Nuclear Medicine</i> , 2017, 58, 27S-33S.	5.0	16
49	Continuation of comprehensive quality control of the <sup>68</sup> Ge/ <sup>68</sup> Ga generator and production of <sup>68</sup> Ga-DOTATOC and <sup>68</sup> Ga-PSMA-HBED-CC for clinical research studies. <i>Nuclear Medicine and Biology</i> , 2017, 53, 37-39.	0.6	8
50	Synthesis and pre-clinical evaluation of a new class of high-affinity <sup>18</sup> F-labeled PSMA ligands for detection of prostate cancer by PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 647-661.	6.4	44
51	Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of <sup>68</sup> Ga 3+, <sup>111</sup> In 3+, <sup>177</sup> Lu 3+ and <sup>225</sup> Ac 3+. <i>Nuclear Medicine and Biology</i> , 2017, 55, 38-46.	0.6	27
52	Phase I dose-escalation study of fractionated-dose <sup>177</sup> Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5093-TPS5093.	1.6	0
53	Preliminary evaluation of prostate-targeted radiotherapy using <sup>131</sup> I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 912-921.	2.4	22
54	Comprehensive Quality Control of the ITC <sup>68</sup> Ge/ <sup>68</sup> Ga Generator and Synthesis of <sup>68</sup> Ga-DOTATOC and <sup>68</sup> Ga-PSMA-HBED-CC for Clinical Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1402-1405.	5.0	41

#	ARTICLE	IF	CITATIONS
55	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 79S-89S.	5.0	200
56	Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration. <i>Annals of the New York Academy of Sciences</i> , 2016, 1363, 125-137.	3.8	33
57	New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 9-15.	7.0	155
58	Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. <i>JCI Insight</i> , 2016, 1, e90064.	5.0	70
59	501. Radioiodinated Adeno-Associated Virus: A Promising New Approach for Monitoring Gene Therapy. <i>Molecular Therapy</i> , 2015, 23, S200.	8.2	0
60	Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. <i>Radiation Research</i> , 2015, 184, 482-493.	1.5	33
61	PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 293-298.	5.0	100
62	Synthesis of [ <sup>11</sup> C]palmitic acid for PET imaging using a single molecular sieve 13X cartridge for reagent trapping, radiolabeling and selective purification. <i>Nuclear Medicine and Biology</i> , 2015, 42, 685-690.	0.6	7
63	Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide <sup>131</sup> I-BA52. <i>Journal of Nuclear Medicine</i> , 2014, 55, 9-14.	5.0	48
64	Radiation dosimetry and first therapy results with a <sup>124</sup> I/ <sup>131</sup> I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1280-1292.	6.4	319
65	Single amino acid chelate complexes of the M(CO) <sub>3</sub> + core for correlating fluorescence and radioimaging studies (M = <sup>99m</sup> Tc or Re). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 255-261.	1.0	42
66	<sup>99m</sup> Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1791-1798.	5.0	125
67	Phase-1 Clinical Trial Results of High-Specific-Activity Carrier-Free <sup>123</sup> I-Iobenguane. <i>Journal of Nuclear Medicine</i> , 2014, 55, 765-771.	5.0	19
68	Synthesis and SAR of Novel Re/ <sup>99m</sup> Tc-Labeled Benzenesulfonamide Carbonic Anhydrase IX Inhibitors for Molecular Imaging of Tumor Hypoxia. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 510-520.	6.4	35
69	First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 380-387.	5.0	201
70	Synthesis and SAR of <sup>99m</sup> Tc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1557-1563.	2.2	78
71	The Role of Copper in Disulfiram-Induced Toxicity and Radiosensitization of Cancer Cells. <i>Journal of Nuclear Medicine</i> , 2013, 54, 953-960.	5.0	71
72	<sup>99m</sup> Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1369-1376.	5.0	193

#	ARTICLE	IF	CITATIONS
73	Dose Escalation Study of No-Carrier-Added <sup>131</sup> I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1155-1163.	5.0	64
74	Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Toxicity of <sup>131</sup> I-Metaiodobenzylguanidine/Topotecan Combination Therapy to Cells and Xenografts That Express the Noradrenaline Transporter. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1146-1154.	5.0	22
75	Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 313-316.	2.8	20
76	Molecular Imaging of Human ACE-1 Expression in Transgenic Rats. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 409-418.	5.3	39
77	Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics. <i>Inorganica Chimica Acta</i> , 2012, 389, 168-175.	2.4	31
78	Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 173-173.	1.6	3
79	<sup>123</sup> I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1087-1093.	5.0	73
80	Novel Polar Single Amino Acid Chelates for Technetium-99m Tricarbonyl-Based Radiopharmaceuticals with Enhanced Renal Clearance: Application to Octreotide. <i>Bioconjugate Chemistry</i> , 2010, 21, 1032-1042.	3.6	60
81	Comparison of High-Specific-Activity Ultratrace <sup>123</sup> I/131 I-MIBG and Carrier-Added <sup>123</sup> I/131 I-MIBG on Efficacy, Pharmacokinetics, and Tissue Distribution. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 299-308.	1.0	67
82	Synthesis, Cytotoxicity, and Insight into the Mode of Action of Re(CO) <sub>3</sub> Thymidine Complexes. <i>ChemMedChem</i> , 2010, 5, 1513-1529.	3.2	35
83	Preclinical Evaluation of an <sup>131</sup> I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 4045-4053.	0.9	48
84	Phase I Trial of <sup>90</sup> Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1524-1531.	5.0	72
85	One Year Follow-Up for the Phase I MTD Study of Ultratrace Iobenguane I <sup>131</sup> I in Patients With Malignant Pheochromocytoma/Paraganglioma (Pheo). <i>Pancreas</i> , 2010, 39, 272.	1.1	0
86	Iodofilic Acid I 123 (BMIPP) Fatty Acid Imaging Improves Initial Diagnosis in Emergency Department Patients With Suspected Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 290-299.	2.8	65
87	Synthesis and Characterization of Rhenium and Technetium-99m Labeled Insulin. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2612-2621.	6.4	24
88	Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 6932-6940.	0.9	279
89	Comprehensive Radiolabeling, Stability, and Tissue Distribution Studies of Technetium-99m Single Amino Acid Chelates (SAAC). <i>Bioconjugate Chemistry</i> , 2009, 20, 1625-1633.	3.6	43
90	Radiation Dosimetry, Pharmacokinetics, and Safety of Ultratrace Iobenguane I- <sup>131</sup> I in Patients with Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 469-475.	1.0	51

#	ARTICLE	IF	CITATIONS
91	Synthesis and Screening of a Library of Re/Tc-Based Amyloid Probes Derived from $\hat{I}^2$ -Breaker Peptides. <i>Bioconjugate Chemistry</i> , 2008, 19, 1087-1094.	3.6	30
92	Isostructural fluorescent and radioactive probes for monitoring neural stem and progenitor cell transplants. <i>Nuclear Medicine and Biology</i> , 2008, 35, 159-169.	0.6	50
93	Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7933-7943.	6.4	180
94	Synthesis and Evaluation of a Series of $^{99m}\text{Tc}(\text{CO})_3^+$ Lisinopril Complexes for In Vivo Imaging of Angiotensin-Converting Enzyme Expression. <i>Journal of Nuclear Medicine</i> , 2008, 49, 970-977.	5.0	29
95	A kit method for the high level synthesis of $[^{211}\text{At}]\text{MABG}$ . <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 3430-3436.	3.0	56
96	Novel ether-containing ligands as potential $^{99m}\text{Tc}$ heart agents. <i>Inorganic Chemistry Communication</i> , 2007, 10, 1409-1412.	3.9	15
97	Future directions of myocardial fatty acid imaging. <i>Journal of Nuclear Cardiology</i> , 2007, 14, S153-S163.	2.1	11
98	Synthesis and validation of fatty acid analogs radiolabeled by nonisotopic substitution. <i>Journal of Nuclear Cardiology</i> , 2007, 14, S100-S109.	2.1	14
99	Extension of the Single Amino Acid Chelate Concept (SAAC) to Bifunctional Biotin Analogues for Complexation of the $\text{M}(\text{CO})_3^+$ Core (M = Tc and Re): Syntheses, Characterization, Biotinidase Stability, and Avidin Binding. <i>Bioconjugate Chemistry</i> , 2006, 17, 579-589.	3.6	45
100	Isostructural Re and $^{99m}\text{Tc}$ Complexes of Biotin Derivatives for Fluorescence and Radioimaging Studies. <i>Bioconjugate Chemistry</i> , 2006, 17, 590-596.	3.6	60
101	A New Strategy for Preparing Molecular Imaging and Therapy Agents Using Fluorine-Rich (Fluorous) Soluble Supports. <i>Journal of the American Chemical Society</i> , 2006, 128, 3536-3537.	13.7	44
102	A new bifunctional amino acid chelator targeting the glucose transporter. <i>Inorganica Chimica Acta</i> , 2006, 359, 1603-1612.	2.4	28
103	Developing the $\text{M}(\text{CO})_3^+$ Core for Fluorescence Applications: Rhenium Tricarbonyl Core Complexes with Benzimidazole, Quinoline, and Tryptophan Derivatives. <i>Inorganic Chemistry</i> , 2006, 45, 3057-3066.	4.0	79
104	Complexes of the $\{\text{ReVOX}_2\}^+$ (X=Cl, Br) core with single amino acid chelate derivatives. <i>Inorganica Chimica Acta</i> , 2005, 358, 2413-2421.	2.4	11
105	Bifunctional chelates with mixed aromatic and aliphatic amine donors for labeling of biomolecules with the $\{\text{Tc}(\text{CO})_3\}^+$ and $\{\text{Re}(\text{CO})_3\}^+$ cores. <i>Inorganica Chimica Acta</i> , 2005, 358, 3691-3700.	2.4	15
106	Metabolic Imaging With $\hat{I}^2$ -Methyl- p -[ $^{123}\text{I}$ ]-Iodophenyl-Pentadecanoic Acid Identifies Ischemic Memory After Demand Ischemia. <i>Circulation</i> , 2005, 112, 2169-2174.	1.6	191
107	A New Strategy for the Preparation of Peptide-Targeted Technetium and Rhenium Radiopharmaceuticals. The Automated Solid-Phase Synthesis, Characterization, Labeling, and Screening of a Peptide-Ligand Library Targeted at the Formyl Peptide Receptor. <i>Bioconjugate Chemistry</i> , 2005, 16, 1189-1195.	3.6	23
108	A convenient solid-phase synthesis methodology for preparing peptide-derived molecular imaging agents – Synthesis, characterization, and in vitro screening of $\text{Tc}(\text{I})$ – chemotactic peptide conjugates. <i>Canadian Journal of Chemistry</i> , 2005, 83, 2060-2066.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Thiol- and Thioether-Based Bifunctional Chelates for the $\{M(CO)_3\}^+Core$ (M = Tc, Re). <i>Inorganic Chemistry</i> , 2005, 44, 6763-6770.	4.0	57
110	Rhenium Tricarbonyl Core Complexes of Thymidine and Uridine Derivatives. <i>Inorganic Chemistry</i> , 2005, 44, 2198-2209.	4.0	62
111	New directions in the coordination chemistry of $^{99m}Tc$ : a reflection on technetium core structures and a strategy for new chelate design. <i>Nuclear Medicine and Biology</i> , 2005, 32, 1-20.	0.6	183
112	N,N-Bis(2-mercaptoethyl)methylamine: A New Coligand for Tc-99m Labeling of Hydrazinonicotinamide Peptides. <i>Bioconjugate Chemistry</i> , 2005, 16, 885-902.	3.6	18
113	Direct Reductive Alkylation of Amino Acids: Synthesis of Bifunctional Chelates for Nuclear Imaging. <i>Synthesis</i> , 2004, 2004, 1759-1766.	2.3	7
114	Complexes of the $fac\text{-}\{Re(CO)_3\}^+$ core with tridentate ligands derived from arylpiperazines. <i>Inorganica Chimica Acta</i> , 2004, 357, 1499-1516.	2.4	47
115	Bifunctional chelates with aliphatic amine donors for labeling of biomolecules with the $\{Tc(CO)_3\}^+$ and $\{Re(CO)_3\}^+$ cores: the crystal and molecular structure of $[Re(CO)_3\{(H_2NCH_2CH_2)_2N(CH_2)_4CO_2Me\}]Br$ . <i>Inorganic Chemistry Communication</i> , 2004, 7, 481-484.	3.9	21
116	A convenient synthesis, chemical characterization and reactivity of $[Re(CO)_3(H_2O)_3]Br$ : the crystal and molecular structure of $[Re(CO)_3(CH_3CN)_2]Br$ . <i>Inorganic Chemistry Communication</i> , 2004, 7, 1023-1026.	3.9	131
117	Bridging the Gap between in Vitro and in Vivo Imaging: Isostructural Re and $^{99m}Tc$ Complexes for Correlating Fluorescence and Radioimaging Studies. <i>Journal of the American Chemical Society</i> , 2004, 126, 8598-8599.	13.7	200
118	Unusual Reactivity of the $\{ReVO\}_3^+$ Core: Syntheses and Characterization of Novel Rhenium Halide Complexes with N-Methyl-o-diaminobenzene. <i>Inorganic Chemistry</i> , 2004, 43, 6445-6454.	4.0	26
119	A New Strategy for the Preparation of Peptide-Targeted Radiopharmaceuticals Based on an Fmoc-Lysine-Derived Single Amino Acid Chelate (SAAC). Automated Solid-Phase Synthesis, NMR Characterization, and in Vitro Screening of fMLF(SAAC)G and fMLF[(SAAC) $^+Re(CO)_3$ ] $^+$ G. <i>Bioconjugate Chemistry</i> , 2004, 15, 128-136.	3.6	112
120	Rhenium tricarbonyl core complexes with ligands derived from arylpiperazines. The structures of $[Re(CO)_3\{NC_5H_4CH_2N(H)CH_2CH_2\}Fphenpip]Br$ , $[Re(CO)_3\{(NC_5H_4CH_2)_2N(CH_2)_3\}CH_3OphenpipH]Br_2$ and $[Re(CO)_3\{(CH_3N_2C_3H_2CH_2)(O_2CCH_2)N(CH_2)_3\}CH_3OphenpipH_2]BrCl$ . <i>Inorganic Chemistry Communication</i> , 2003, 6, 1099-1103.	3.9	17
121	$\{ReIII Cl_3\}$ Core Complexes with Bifunctional Single Amino Acid Chelates. <i>Inorganic Chemistry</i> , 2002, 41, 5795-5802.	4.0	18
122	Bifunctional Single Amino Acid Chelates for Labeling of Biomolecules with the $\{Tc(CO)_3\}^+$ and $\{Re(CO)_3\}^+$ Cores. Crystal and Molecular Structures of $[ReBr(CO)_3(H_2NCH_2C_5H_4N)]$ , $[Re(CO)_3\{(C_5H_4NCH_2)_2NH\}]Br$ , $[Re(CO)_3\{(C_5H_4NCH_2)_2NCH_2CO_2H\}]Br$ , $[Re(CO)_3\{X(Y)NCH_2CO_2CH_2CH_3\}]Br$ (X = Y = 2-pyridylmethyl; X = 2-pyridylmethyl, Y =) <i>Inorganic Chemistry</i> , 2002, 41, 1711-1712.	4.0	171
123	Synthesis, characterization, and biodistribution of a Technetium-99m $\text{ac}^3+1\text{ac}^m$ fatty acid derivative. The crystal and molecular structures of a series of oxorhenium model complexes. <i>Inorganica Chimica Acta</i> , 2002, 338, 149-156.	2.4	24
124	Mapping of local renal blood flow with PET and $H_2(15)O$ . <i>Journal of Nuclear Medicine</i> , 2002, 43, 470-5.	5.0	36
125	Rhenium(I) Carbonyl Complexes of 2,4,6-Tris(2-pyridyl)-1,3,5-triazine (TPT). Rhenium(I)-Promoted Methoxylation of the Triazine Ring Carbon Atom in Dinuclear Rhenium Complexes. <i>Inorganic Chemistry</i> , 2001, 40, 2769-2777.	4.0	49
126	$[^{111}C,^{127}I]$ Altropane: A highly selective ligand for PET imaging of dopamine transporter sites. <i>Synapse</i> , 2001, 39, 332-342.	1.2	57

#	ARTICLE	IF	CITATIONS
127	Spectroscopic and structural studies of complexes of the fac-[Re(Nâˆ©N)(CO)3L]n+ type (Nâˆ©N=2-(2-pyridyl)benzothiazole; L=Cl, Br, CF3SO3âˆ©, CH3CN). <i>Inorganica Chimica Acta</i> , 2001, 314, 91-96.	2.4	26
128	Synthesis and structural characterization of rhenium(I) tricarbonyl complexes with the bidentate ligands o-(diphenylphosphino)benzaldehyde (Pâˆ©O) and o-[(diphenylphosphino)benzylidene]aniline (Pâˆ©N). <i>Inorganica Chimica Acta</i> , 2001, 315, 147-152.	2.4	41
129	Synthesis, characterization and crystal structures of mono-, di- and trinuclear rhenium(I) tricarbonyl complexes with 2,3,5,6-tetra(2-pyridyl)pyrazine. <i>Inorganica Chimica Acta</i> , 2001, 315, 66-72.	2.4	28
130	Schiff base chemistry of the rhenium(V)-oxo core with âˆ©3+2âˆ©™ ligand donor sets. <i>Inorganica Chimica Acta</i> , 2001, 316, 33-40.	2.4	24
131	Synthesis and characterization of a âˆ©3+2âˆ©™ {Re(V)O}3+ core complex carrying the ONS/PO donor atom set. <i>Inorganica Chimica Acta</i> , 2001, 316, 145-148.	2.4	12
132	6-Mercaptomethylpyridine-3-carboxylic acid (MEMNIC): a new reagent for peptide labeling with Tc-99m. <i>Inorganica Chimica Acta</i> , 2001, 323, 23-36.	2.4	14
133	Novel monoamine transporter ligands reduce cocaine-induced enhancement of brain stimulation reward. <i>Pharmacology Biochemistry and Behavior</i> , 2001, 68, 171-180.	2.9	3
134	Synthesis and characterization of complexes of the {ReO}3+ core with SNS and S donor ligands. <i>Inorganica Chimica Acta</i> , 2000, 306, 30-37.	2.4	21
135	Structural characterizations of an Re(IV) complex [ReCl4(OPPh3)2] and of an imino species [ReOCl2(PPh3)(î-2-OC6H4-2-CHî...NH)] prepared from the reaction of [ReOCl3(PPh3)2] with salicylaldehyde. <i>Inorganica Chimica Acta</i> , 2000, 306, 112-115.	2.4	8
136	Investigations of the {ReO}3+ core: A âˆ©2+2âˆ©™ complex from bidentate and potentially tridentate ligands: [ReO(î-2-HOC6H4-2-CH2NC6H4S)(î-2-SC5H4N)(PPh3)]. <i>Inorganica Chimica Acta</i> , 2000, 306, 38-41.	2.4	6
137	Schiff base chemistry of the {ReO}3+ core: structural characterization of the unusual âˆ©3+2âˆ©™ complex [ReO(î-3-OC6H4âˆ©“CHî...NC6H4-2-S)(î-2-OC6H4)]. <i>Inorganica Chimica Acta</i> , 2000, 307, 149-153.	2.4	28
138	Exploring oxorhenium âˆ©3+1âˆ©™ mixed-ligand complexes carrying the S-benzyl-3-[(2-hydroxyphenyl)methylene]dithiocarbamate [ONS]/monothiol [S] donor set: synthesis and characterization. <i>Inorganica Chimica Acta</i> , 2000, 307, 154-159.	2.4	22
139	Synthesis and crystal and molecular structure of a tetranuclear cluster based on the rhenium(III)-bisorganohydrazino core: [Re(HNNC4H3N2)(NNC4H3N2)(OCH3)2]4. <i>Inorganica Chimica Acta</i> , 2000, 307, 160-163.	2.4	9
140	Synthesis and characterization of oxorhenium(V)âˆ©3+1âˆ©™ mixed thiolate [SNS]/[S] and [ONS]/[S] complexes. Crystal and molecular structures of [ReO(î-3-SCH2C5H3NCH2S)(î-1-C6H4Br-4-S)], [ReO(î-3-SCH2C5H3NCH2O)(î-1-C6H4X-4-S)] (X=Cl, OMe), [ReO(î-3-SCH2C5H3NCH2O)(î-1-C6H4OCH3-4-CH2S)] and [ReO(î-3-SCH2C5H3NCH2S)(î-1-C5H4NH-2-S)] [Cl]. <i>Inorganica Chimica Acta</i> , 2000, 307, 88-96.	2.4	19
141	The syntheses and structures of âˆ©3+2âˆ©™ and âˆ©2+2+1âˆ©™ oxorhenium mixed-ligand complexes employing 8-hydroxy-5-nitroquinoline as the bidentate N,O donor ligand. <i>Inorganica Chimica Acta</i> , 2000, 308, 80-90.	2.4	53
142	99mTc-labeled chemotactic peptides: influence of coligand on distribution of molecular species and infection imaging properties. Synthesis and structural characterization of model complexes with the {Re(î-2-HNNC5H4N)(î-1-NNC5H4N)} core. <i>Inorganica Chimica Acta</i> , 2000, 309, 123-136.	2.4	33
143	An unexpected âˆ©4+2âˆ©™ [N3S]/[NS] rhenium(IV) complex formed upon cleavage of a Re(V) imido bond. <i>Inorganica Chimica Acta</i> , 2000, 310, 237-241.	2.4	10
144	Syntheses and structural characterization of rhenium-bis-hydrazinopyrimidine core complexes with thiolate and Schiff base coligands. <i>Inorganica Chimica Acta</i> , 2000, 310, 210-216.	2.4	9

#	ARTICLE	IF	CITATIONS
145	Cationic complexes of the $\text{Re}^{3+}$ oxorhenium-thiolate family. <i>Inorganica Chimica Acta</i> , 2000, 297, 98-105.2.4		37
146	Synthesis and biological evaluation of two novel DAT-binding technetium complexes containing a piperidine based analogue of cocaine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 3211-3216.	2.2	14
147	Synthesis and characterization of oxorhenium- $3+1$ mixed-thiolate complexes. Crystal and molecular structures of $[\text{ReO}(\text{SCH}_2\text{CH}_2)_2\text{S}(\text{C}_6\text{H}_4\text{X}-4\text{-CH}_2\text{S})]$ (X=F, Cl, Br, OMe) and of the pendant thiolate compounds $[\text{ReO}(\text{SCH}_2\text{CH}_2)_2\text{S}(\text{SCH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{SH})]$ and $[\text{ReO}(\text{SCH}_2\text{CH}_2)_2\text{S}(\text{SCH}_2\text{CH}(\text{OH})\text{CH}(\text{OH})\text{CH}_2\text{SH})]$ . <i>Inorganica Chimica Acta</i> , 1999, 284, 252-257.	2.4	36
148	Targeted imaging of infection. <i>Advanced Drug Delivery Reviews</i> , 1999, 37, 237-252.	13.7	9
149	Altoprane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. , 1998, 29, 116-127.		50
150	Rapid detection of Parkinson's disease by SPECT with altoprane: A selective ligand for dopamine transporters. , 1998, 29, 128-141.		104
151	Altoprane, a SPECT or PET imaging probe for dopamine neurons: I. dopamine transporter binding in primate brain. <i>Synapse</i> , 1998, 29, 93-104.	1.2	36
152	Synthesis and structural characterization of the neutral indium (III) thiolate species $\text{In}(\text{SCH}_2\text{CH}_2)_3\text{N}$ . <i>Inorganic Chemistry Communication</i> , 1998, 1, 164-166.	3.9	6
153	Expansion of the $\text{Re}^{3+} + 1$ concept of oxorhenium-thiolate chemistry to cationic and binuclear complexes. <i>Inorganic Chemistry Communication</i> , 1998, 1, 209-212.	3.9	22
154	Synthesis and Characterization of Organohydrazino Complexes of Technetium, Rhenium, and Molybdenum with the $\{\text{M}(\text{L}-\text{HxNRR})(\text{L}-\text{HyNRR})\}$ Core and Their Relationship to Radiolabeled Organohydrazine-Derivatized Chemotactic Peptides with Diagnostic Applications. <i>Inorganic Chemistry</i> , 1998, 37, 2701-2716.	4.0	91
155	Pharmacokinetics of [ <sup>18</sup> F]Trovafloracin in Healthy Human Subjects Studied with Positron Emission Tomography. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2048-2054.	3.2	58
156	The Role of Positron Emission Tomography in Pharmacokinetic Analysis. <i>Drug Metabolism Reviews</i> , 1997, 29, 923-956.	3.6	67
157	Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 538-543.	2.1	16
158	Pharmacokinetics of <sup>18</sup> F-labeled trovafloracin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography. <i>Clinical Microbiology and Infection</i> , 1997, 3, 63-72.	6.0	18
159	Thermal injury in rats alters glucose utilization by skin, wound, and small intestine, but not by skeletal muscle. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1161-1167.	3.4	24
160	<sup>18</sup> F-labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloracin (CP) Tj ETQq0 0 0 rgrBT /Overlock 10 Tf	9.6	28
161	Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of <sup>11</sup> C-CFT. , 1996, 24, 262-272.		33
162	Synthesis of a <sup>11</sup> C-labeled NK1 receptor ligand for PET studies. <i>Nuclear Medicine and Biology</i> , 1995, 22, 31-36.	0.6	16

#	ARTICLE	IF	CITATIONS
163	Comparison of the infection imaging properties of a <sup>99m</sup> Tc labeled chemotactic peptide with <sup>111</sup> In IgG. <i>Nuclear Medicine and Biology</i> , 1995, 22, 643-648.	0.6	42
164	Positron Emission Tomography: Clinical Applications and Pharmaceutical Care. <i>Journal of Pharmacy Practice</i> , 1994, 7, 124-139.	1.0	1
165	Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement usina a trapped tracer model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994, 21, 336-341.	2.1	41
166	Synthesis of [ <sup>11</sup> C]dapoxetine · HCl, a serotonin re-uptake inhibitor: Biodistribution in rat and preliminary PET imaging in the monkey. <i>Nuclear Medicine and Biology</i> , 1994, 21, 669-675.	0.6	27
167	Infection imaging with technetium-99m-labeled chemotactic peptide analogs. <i>Seminars in Nuclear Medicine</i> , 1994, 24, 154-168.	4.6	42
168	Imaging of focal sites of inflammation in rhesus monkeys with <sup>99m</sup> Tc-labeled human polyclonal IgG. <i>Nuclear Medicine and Biology</i> , 1994, 21, 111-116.	0.6	9
169	Synthesis of 2-[ <sup>18</sup> F]Fluoro-2-deoxy-l-dlucose and positron emission tomography studies in monkeys. <i>Nuclear Medicine and Biology</i> , 1994, 21, 633-640.	0.6	1
170	Synthesis and biodistribution of <sup>18</sup> F-labeled Fleroxacin. <i>Nuclear Medicine and Biology</i> , 1993, 20, 81-87.	0.6	20
171	Development of a high performance zinc-62/copper-62 radionuclide generator for positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 418-25.	2.1	40
172	Preoperative imaging of colorectal cancers. Targeting the epithelial membrane antigen with a radiation-labeled monoclonal antibody. <i>Cancer</i> , 1992, 69, 620-625.	4.1	11
173	An evaluation of <sup>99m</sup> Tc-HMPAO uptake in cerebral gliomas ?a comparison with X-ray CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1990, 16, 293-298.	2.1	7